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Catecholamines given in high concentrations produce myocardial damage in several mamma-
lian species. The histological changes are similar to those found in patientsgiven largeamounts of
pressor agents and in those who develop pheochromocytomas. They include myofiber necrosis,
myofibrillar degeneration, and mononuclear leukocytic infiltration. Cardiac function is signifi-
cantly impaired. Endogenous release of catecholamines can also induce myocardial injury in
rabbits infused with tyramine. Anatomic and functional abnormalities described in various
models ofcatecholamine cardiomyopathy are summarized. The several major theories regarding
pathogenesis are reviewed. Recent data suggesting that 02-derived free radical generation is
involved are discussed.
It has been recognized for several decades that sympathetic agonists can cause
significant myocardial damage in experimental models and in human hearts. Morpho-
logical changes include myofiber necrosis and a predominantly mononuclear leukocytic
infiltrate. The lesions are similar to those found in patients given large amounts of
pressor agents to treat shock states, and in those who develop pheochromocytomas.
Mechanical function is substantially impaired.
A range of mechanisms has been proposed to explain the morphological and
functional damage. Early workers suggested that elevated concentrations offree fatty
acids induced by catecholamines were toxic to myocytes. A second hypothesis involved
platelet aggregation with microvascular obstruction. Neither possibility has withstood
subsequent analysis. While calcium overload has been repeatedly demonstrated in
dead or dying cells, evidence would suggest that this condition is a secondary event.
Alpha receptor blockade has been shown to inhibit both coronary vasoconstriction and
myocyte injury by norepinephrine, suggesting an ischemic mechanism. Allopurinol is
also effective, but preservation of purine pools may not be a critical consideration.
Recent studies suggest a common denominator involving the generation of02-derived
free radicals as the primary mechanism leading to membrane damage and myocyte
death.
The purpose ofthis review is to describe the anatomic and functional abnormalities
encountered in various models of catecholamine injury and to discuss evidence
supporting the several mechanisms proposed to explain the pathogenesis of this
process.
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PATHOLOGY OF CATECHOLAMINE CARDIOMYOPATHY
The histological and ultrastructural changes ofcatecholamine cardiomyopathy have
been well characterized [1-101. Shortly after large doses are given, focal and diffuse
subendocardial hemorrhages are visible on gross examination [4,9,11-13]. Hemor-
rhage has also been noted in the myocardium and epicardium [4]. Within 48 hours,
well-demarcated lesions appear, involving particularly the apical portion of the heart.
The tricuspid, mitral, and aortic valves often become edematous and distorted, and
commonly are hemorrhagic [11,12]. Fibrosis begins to appear at about the fourth or
fifth day, with formation of indistinct linear scars. Aneurysms also occasionally occur
in the fibrotic area [14].
Early histological findings include interstitial edema, subendocardial congestion,
and hemorrhages [9]. Myofibrillar degeneration has been demonstrated as early as two
to three minutes following a bolus injection ofthe agonist [2]. An interstitial inflamma-
tory response composed primarily ofmononuclear cells appears within six to ten hours
and is most intense in the subendocardium [1,9,13,15]. Lymphocytes, granulocytes,
and perivascular Anitschkoff myocytes are also present in the inflammatory infiltrate
[1,5,7,9]. Numerous contraction bands may occur as well [16,17]. These represent
irregular, acidophilic condensations of the contractile proteins, in combination with
hypercontracted sarcomeres.
After 72 hours, thin bands of collagenous connective tissue appear, and numerous
fibroblasts can be identified [7,9]. Resorption ofnecrotic muscle fibers and granulation
tissue becomes prominent by the sixth day [18]. Sheets of histiocytes and fibroblasts
appear, suggesting a granulomatous reaction [8,9]. These reactive areas are progres-
sively replaced by fibrous tissue [5]. By two weeks, only scar remains.
Yunge et al. [19] studied isoproterenol-induced myocyte injury by using freeze-
fracture electron microscopy and the extracellular diffusion tracer, horseradish peroxi-
dase. They found myocytes exhibited significant loss of integral proteins of the
sarcolemmal membrane as early as ten minutes after injection. Small irregular tears
were prominent. These findings, together with the decrease in intramembrane particle
densities, suggested that cell leakage was likely.
MECHANICAL DYSFUNCTION IN NOREPINEPHRINE-INJURED
HEARTS
In vivo functional abnormalities have been shown to correlate with histopathological
changes. Werner et al. [20] studied the capacity of the cardiomyopathic left ventricle
to respond to afterload stresses. They demonstrated that in norepinephrine-(NE-)
injured hearts, pressure function curves were significantly lower than in control
animals, consistent with depressed left ventricular performance. Fripp et al. [21]
studied a measure ofcontractile elementvelocity (dP/dt) in similar preparations. They
found that the resting dP/dtma, did not differ from control hearts, suggesting no
difference in the resting contractile state. Inotropic responsiveness to NE and calcium
stimulation were, however, markedly reduced in the injured hearts. This condition was
manifested by a lesser proportional increase in dP/dtma,, during NE or calcium
administration. Since the responses to both agents were diminished, it is unlikely that
the abnormality is limited to the adrenergic receptor system, but probably includes
other mechanisms, such as excitation-contraction coupling [21].
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We have also studied left ventricular pump function in these preparations, using
standard ventricular function curves [17]. Mean stroke volume at left ventricular end
diastolic pressure of 10 cm H2O(SVI0) was 20 percent lower in the injured hearts than
in the controls. The ability to augment global pump function with inotropic stimulation
was, however, similar to that of control animals. These studies confirmed that in
catecholamine cardiomyopathy there is a dissociation ofvelocity (dP/dtma,) and force
(SVI0) responses. A similar dissociation has been identified in other circumstances,
including myocardial infarction and circulatory shock [17].
PATHOGENESIS OF CATECHOLAMINE CARDIOMYOPATHY
Over the years, a number of mechanisms have been proposed to explain the
pathogenesis ofcatecholamine cardiomyopathy. Some ofthe more prominent concepts
will be reviewed. Although a definitive conclusion cannot be reached at this time,
present evidence indicates that several of the previously proposed mechanisms are
untenable. A common pathway involving free radical generation is the most likely
candidate to explain the injury process.
Fatty Acid Toxicity
Maling and Highman (1958) first noted that fatty degeneration is a typical feature
of myocardial lesions resulting from infusion of levarterenol. They hypothesized that
the appearance of fat droplets in the myocardial fibers reflected altered lipid metabo-
lism which injured the myocytes [11]. This theory was supported by the findings of
Norkin et al. [22], who demonstrated that long-chain fatty acids are cytotoxic to cells
in tissue culture and can induce acute myocardial failure in dogs when injected
intravenously in the unbound state [23]. Hoak et al. [13] suggested that elevated free
fatty acids (FFA) in myocytes may cause uncoupling ofoxidative phosphorylation and
direct myocardial tissue damage. Increased FFA may also modify the lipid bilayer of
the sarcolemmal membrane and indirectly alter membrane protein function [24].
Quantitative relationships between elevated FFA levels and degrees of ischemic
injury have been identified. Plasma FFA concentrations are significantly increased in
patients with acute myocardial infarction and cerebral vascular occlusion [25]. Those
with serum FFA concentrations above 1,200 mEq/liter following an acute myocardial
infarction are more likely to suffer serious arrhythmias or death [26]. In a necropsy
study, patients who died following acute myocardial infarction had the highest serum
FFA concentration ofany group [27].
Catecholamines increase plasma FFA by stimulating the mobilization oflipids from
adipose tissues [13]. Hence, the foregoing observations provide a potential mechanism
for myocyte injury. Others have found, however, that FFA, phospholipases, and
lysophosphatides have little effect on dog myocardium, even during severe ischemia
[28]. Moreover, the very high levels of FFA necessary to induce myocardial injury
have never been found inexperimental ornaturallyoccurringcatecholamine cardiomy-
opathy. Dogs were used in mostofthe studies mentioned. Schenkand Moss [9] showed
that rabbits develop identical myocardial lesions after administration of levarterenol.
Unlike dogs, there is little increase in the plasma FFA concentration in this species.
Hence, fatty acids probably contribute little or nothing to the pathogenesis ofmyocyte
injury.
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Platelet Aggregation
In theearly 1970s, Haft and colleagues proposed that intravascular platelet aggrega-
tion is the primary pathogenetic mechanism responsible for myocyte injury by the
catecholamines [29-31]. Cannon and Gray [32] demonstrated in 1914 that sympa-
thetic hormones enhance coagulation ofblood. In vitro experiments have subsequently
shown that epinephrine and norepinephrine promote platelet aggregation [33-35].
Studies by Haft et al. [29] found that the extent ofinjury was reduced when dogs were
pre-treated with platelet inhibitors such as aspirin and dipyridamole prior to epineph-
rine infusion. Using electron microscopy, this group found platelet aggregates in small
vessels immediately following four hours ofnorepinephrine infusion [30]. All stages of
aggregation were identified, ranging from a few adherent platelets to platelet plugs
completely occluding the vessel. In most, the endothelial surface appeared intact,
suggesting that the platelet aggregation was not secondary to endothelial damage.
To determineexperimentally ifendogenouscatecholamine release can cause platelet
aggregation, rats were exposed to various environmental stresses, including cold water
[36], hot water [37], and hemorrhage [37]. Overall, 87 to 100 percent of the animals
had coronary intravascular platelet aggregation, but they were identified in only 7
percent ofcontrols.
Kammermeierand Ober [38] havereported thatanimalspre-treatedwithantithrom-
bocyte serum or a prostacycline analog suffer less injury from isoproterenol. Other
investigators were, however, unable to confirm the appearance of platelet aggregates
after catecholamine administration [8]. It is known that alpha agonists may induce
platelet aggregation via the alpha-2 receptors, but beta receptor stimulation has never
been shown to promote platelet activation. Thus, a different mechanism must be
invoked to explain injury by isoproterenol, a pure beta agonist. Fibrinogen or other
local factors which activate the coagulation cascade could be involved, as may
vasoconstriction by initiating microvascular platelet aggregation. This process could
also be a secondary event following initial myocyte damage, as occurs in ischemic
cardiac injury. Nevertheless, most recent studies have failed to identify the presence of
microthrombi sufficient to explain the myocyte injury [3,10,16,19].
Hypercontraction Hypothesis
Fleisher and Loeb suggested many years ago that myocardial injury caused by
adrenaline is the result of violent muscle contractions [39]. Csapo et al. [40] studied
the early electron microscopic changes from isoproterenol administration. They found
that injured myocytes demonstrated characteristic changes of hypercontraction of
myofilaments with formationofcontractionbands, anddisorganization and fragmenta-
tion of myofibrils. It has been shown that insulin substantially reduces contractility
responses to norepinephrine (NE) in isolated cardiac muscle preparations and in the
intact swine heart [41,42]. Insulin also reduces myofiber injury in rabbits given NE.
This fact suggested a linkage between inotropic stimulation and catecholamine cardio-
myopathy [3].
Subsequent studies [10,43,44] failed to support a causal relationship between
inotropic activity and cardiac injury. Beta-blocking drugs, such as propranolol and
practolol, which abolish inotropic responses, have no significant effect on NE-induced
damage in the rabbit model. Rather, the alpha-antagonist phentolamine largely
prevents lesion formation. The alpha agonist methoxamine, which has little or no
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inotropic action, causes lesions identical to those produced with NE. The severity of
injury is dose-dependent. Thedemonstration that prazosin, but not yohimbine, reduces
the extent of injury indicates that the alpha, receptor system is involved [45]. These
studies demonstrate a clear dissociation between excess mechanical activity following
beta adrenergic stimulation and myofiber necrosis.
Calcium Overload
Catecholamines cause increased calcium transport into myocytes [46]. Some have
suggested that this effect may result in ATP hydrolysis leading to myocardial injury.
Opie et al. [47] showed that lowering the calcium concentration in the perfusate and
the use of calcium antagonists both reduce the extent of injury by catecholamine. No
alterations in myocardial high-energy phosphate stores were identified. These experi-
ments suggested that changes in myofiber calcium translocation, uptake, and binding
through alpha, receptor activation may be factors contributing to membrane damage
[43].
Increased cytosolic calcium concentrations could have detrimental effects in several
different ways. Calcium-dependent phospholipases may be activated and lead to
increased production of FFA and lysophospholipids. Many important intracellular
enzymes, such as proteases, nucleases, adenylate cyclases, Na-K-ATPases, and glyco-
gen phosphorylases could be altered and lead to cellular injury. If, however, calcium
overload is to beimplicated as theprimary mechanism, it must be shown that increased
cytosolic calcium appears prior to the irreversible phase ofcell injury. This hypothesis
has been very difficult to prove, primarily because of uncertainties in defining the
transition from reversible to irreversible cell injury. The finding ofincreased intracellu-
lar calcium does not by itself prove the calcium overload theory. The possibility
remains that influx of calcium takes place after the plasma membrane and cell are
irreversibly damaged.
Coronary Vasoconstriction
Ischemia has been suggested as a potentially important factor in the pathogenesis of
catecholamine cardiomyopathy. Handforth [48] infused India ink into the coronary
arteries ofhamsters sacrificed shortly after isoproterenol administration; he found that
flow to the subendocardium was markedly reduced. This result suggested that the
cardiac injury was due either to localized vasoconstriction or shunting of blood away
from the subendocardial layer, causing ischemic necrosis. NE has also been shown to
cause a reduction in absolute subendocardial flow, and in the subendocardial-to-
epicardial flow ratio in isolated canine heart preparations [49]. Histological changes in
catecholamine damage are most prominent in the subendocardium. A significant rise
in coronary artery resistance occurs minutes after starting the infusion of NE in
conscious dogs, and phentolamine blocks this response [50]. In these animals, there
was a 92 percent increase in coronary resistance after giving methoxamine, indicating
substantial alpha receptor-mediated coronaryvasoactivity.
More recent studies in a rabbit model support the hypothesis that norepinephrine
injury may involve ischemia and alpha adrenergic pathways [44]. Coronary flow rates
measured with radioactive microspheres fell by nearly 45 percent within 40 minutes of
NE infusion (3 ,ug/minute/kg). Pre-treatment with phentolamine abolished this
response. In related studies [3,17], however, no evidence for a supply-demand mis-
match which might cause ischemic injury was found. It is also noteworthy that the
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pathology ofcatecholamine injury is inconsistent with acute ischemic damage to heart
muscle. Lesions 48 hours after NE show a primarily mononuclear infiltrate, in contrast
with the predominantly polymorphonuclear infiltrate found following ischemic injury
[10,21]. This finding does not rule out the possibility that reperfusion after relative
ischemia may contribute to the injury and possibly modify the usual histological
features ofischemic necrosis.
Free Radical Hypothesis
Several reports using rats suggest that highly cytotoxic free radicals from catechol-
amine autoxidation are involved in the genesis of myocyte damage [51-53]. Peroxida-
tion ofmembrane phospholipids resulting in permeability changes is presumed to form
the basis for intracellular calcium overload. The latter is probably responsible for
inducing arrhythmias, abnormal metabolism, structural damage, and contractile
failure. Some [51] have proposed that oxidation products ofthe catecholamines, such
as the free radical adrenochrome, play a major role. When fresh isoproterenol or
epinephrine isgiven, itdoes not induceinjury in isolated rat heart preparations. Lesions
do appear when the hearts are perfused with isoproterenol that has undergone
oxidation, however. Administration of adrenochromes induces similar lesions and
significant contractile dysfunction [51].
Hydrogen peroxide and hydroxyl radicals can also be generated by catecholamine
metabolism through the monoamine oxidase system because an oxidation reaction is
involved. Singal et al. [54,55] showed that rats, pre-treated with either vitamin E or
zinc, developed significantly less injury from isoproterenol. They suggested that
vitamin E, an antioxidant, protected the myocardium by directly scavenging free
radicals. Zinc, on the other hand, has a membrane-stabilizing effect which presumably
diminished radical-induceddamage. Themechanismofradicalgenerationbycatechola-
mines remains unproven, however, and could involve more than one pathway.
Role ofReperfusion and Oxygen Free Radical Generation
Because severe coronary vasoconstriction is associated with exposure to catechol-
amines [44,48-50], reperfusion injury may be an important pathway. Reperfusion of
ischemic myocardium provides a potential means ofpreventing cell death. During the
reversible phase, however, it can also accelerate the process of cell death and elicit
potentially lethal ventricular arrhythmias [56-58]. Although the precise pathogenetic
mechanisms remain controversial, attention has focused recently on the contribution of
oxygen-derived free radicals [60-64]. Shlafer et al. [65] studied isolated cat hearts
with global ischemia. They found that ventricular pressure development, dP/dtmax, and
coronary blood flow weresignificantly improved followingreperfusion when superoxide
dismutase (SOD) and catalase were added to the cardioplegia solution. Effectiveness
of these scavengers in this and other studies [66,67] suggests that oxygen free radicals
contribute to reperfusion injury.
Otani et al. [68] showed that when mitochondria isolated from globally ischemic
rabbit hearts are incubated with SOD and catalase, ATP production is enhanced
during aerobic respiration. Using electron spin resonance spectroscopy, they also
demonstrated that signals detected from hydroxyl radicals are markedly suppressed in
the presence of these scavengers. There is evidence at the tissue level that oxygen
radicals induce irreversible myocardial damage. Studies in canine models [69,70] have
shown a significant reduction in infarct size in animals treated with SOD and catalase.
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It is important to note that the myocardial protection is not temporally related to the
duration of treatment during ischemia. Rather, damage by oxygen radicals occurs
primarily during the initial phase ofreperfusion [71].
Oxygen free radicals may arise from a number ofdifferent sources during ischemia
and reperfusion. The major sources presently recognized include: (a) catecholamine
degradation, (b) mitochondrial dysfunction, (c) leukocyte activation, and (d) xanthine
oxidase. Each of these shares a common oxidation step where oxygen can serve as an
electron acceptor. Hence, reperfusion with reintroduction of large amounts of oxygen
would potentially initiate and accelerate the process ofcell injury.
Allopurinol and Cardiomyocyte Preservation
Allopurinol (ALLO) has been extensively studied because of its ability to reduce
ischemia-reperfusion damage to myocardium [72-76]. We recently demonstrated
substantial protection following norepinephrine infusion in the rabbit [88]. Mechani-
cal function in animals not given ALLO was significantly impaired, and this condition
was accompanied by reduced concentrations of ATP and glycogen, and sharply
elevated creatine phosphokinase and lacticdehydrogenase release. There was extensive
myocyte injury assessed by histological analysis. These abnormalities were reduced or
absent in the treated animals. Protection may involve scavenging of free radicals,
suppression of free radical production, or preservation of the adenine nucleotide pool
[63,77,78]. Since both ischemia and free radical generation have been implicated in
the generation ofcatecholamine injury [44,79], the findings are consistent with known
properties ofallopurinol.
During ischemia, xanthine dehydrogenase in endothelial cells is converted in many
species to xanthine oxidase, while the extracellular fluid hypoxanthine concentration is
markedly increased. Hypoxanthine serves as substrate for xanthine oxidase. With
reperfusion, oxygen free radicals are produced, thereby accelerating the process ofcell
death [63,80,81]. Grum et al. [82], however, measured coronary effluent purine
concentrations following myocardial ischemia in rabbits. They found a total absence of
xanthine and uric acid, but an elevated level of hypoxanthine. This efflux profile
strongly suggested the absence of myocardial xanthine oxidase or dehydrogenase in
this species. Hence, other pathways must be implicated to explain the action ofALLO
in the rabbit model.
Free radicals are also produced by activated leukocytes (NADPH oxidase activity)
and, at the mitochondrial level, "superoxide leak" [60,63,81,83]. Ischemia is accompa-
nied by a regional release of NE from sympathetic nerve endings [63]. This process
raises the potential for free radical production through oxidation in the monamine
oxidase system. Hence, the protective action of ALLO in our system could involve
direct scavenging offree radicals. Moorhouse et al. [78] have shown thatALLO and its
metabolites, which are aromatic compounds, function as free radical scavengers in
heart muscle. Its scavenging potential is equal to that ofmannitol. Oxypurinol, a major
degradative product ofALLO, has even higher scavenging capabilities.
Several studies [77,84,85] have suggested that preservation of ATP is an important
additional mechanism wherebyALLO reduces ischemicinjury in myocardium. DeWall
et al. [84] demonstrated, in allopurinol-treated myocardium, enhancement of labeled
hypoxanthine uptake and incorporation into the adenine nucleotide pool [86]. This
hypothesis has been revived recently by Lasley et al. [77], who also found that ALLO
protects ischemic rat myocardium by preserving adenine nucleotide pools. Moreover,
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the administration of hypoxanthine enhanced recovery of function without being
arrhythmogenic. These findings appear contrary to the idea that free radical produc-
tion through the xanthine oxidase system is a significant cause ofischemic injury.
Preservation ofATP may be important in the outcome ofsome ischemic insults, but
this condition does not appear to be true for hearts subjected to catecholamine injury.
Recent data from our laboratory have shown that the mechanical performance of
hearts isolated immediately following 90 minutes of norepinephrine infusion was
impaired, while energy-rich phosphate concentrations remained unchanged [87]. This
dissociation suggests that preservation ofATP does not explain the protective action of
allopurinol in these circumstances.
SUMMARY
Present evidence indicates that two quite disparate mechanisms are involved in the
pathogenesis of catecholamine cardiomyopathy. Alpha adrenergic blockade with
phentolamine or prazosin sharply reduces myocyte injury, suggesting that ischemia
secondary to coronary vasoconstriction could be involved; however, allopurinol is
equally effective. This drug has never been shown to alter adrenergic receptors or
effector pathways. As has been discussed, the available data favor a free radical
scavenging action as the most likely basis for the protective action of allopurinol.
Linkages to a common mechanism are possible, though speculative. Various aromatic
compounds, including ALLO, possess free radical scavenging properties. Because
phentolamine has two aromatic rings, it might be an effective scavenger, though this
fact has not been demonstrated. A second possibility is that, by preventing significant
coronary vasoconstriction, phentolamine prevents ischemia-induced freeradical gener-
ation. Direct evidence regarding these hypotheses must await future investigations.
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